Ver­tex li­cens­es TreeFrog’s tech to up­scale cell ther­a­py man­u­fac­tur­ing for di­a­betes can­di­dates

Ver­tex will pay $25 mil­lion up­front for TreeFrog Ther­a­peu­tics’ cell man­u­fac­tur­ing tech­nol­o­gy that can help boost pro­duc­tion of its ear­ly-phase type 1 di­a­betes as­sets. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Senior Associate - Life Science

Alexandria Real Estate Equities

Seattle, WA, USA